Health
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
NEW YORK, March 19, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC).
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/5ea0646ce09eb2ba1e5731869ecced2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FZld_3nMTn.O06EpYuNG5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNA--/https://media.zenfs.com/en/business-wire.com/5ea0646ce09eb2ba1e5731869ecced2f","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic hormone sensitive prostate cancer","length":230,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Consistent rPFS efficacy benefit was observed in patients whose tumors harbored BRCA and non-BRCA HRR gene alterations","length":118,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Interim analysis showed a strong trend toward improvement in overall survival","length":77,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"These results will be discussed with global health authorities to potentially expand TALZENNA indication in this earlier stage disease","length":134,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":559,"olType":false},{"type":"text","content":"NEW YORK, March 19, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC).","length":503,"tagName":"p"},{"type":"text","content":"The study met its primary endpoint, with TALZENNA plus XTANDI demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS), compared to placebo plus XTANDI. The results markedly exceeded the pre-specified target hazard ratio of 0.63, with the majority of patients remaining progress...